Abstract:Highlights • In this study, we successfully developed an innovative nanodelivery system termed ICG@MnO 2 @Exo-anti-PD-L1 NPs for combining photodynamic therapy (PDT) effect with immunotherapy of non-small cell lung cancer (NSCLC). • The hollow MnO 2 nanoplatform enables a more substantial photosensitizer loading to heighten PDT, and mitigates tumor hypoxia by catalyzing the conversion of H 2 O 2 into O 2 through MnO 2 . • The generation of Mn 2+ through redox reactions due to the high level of intratumoral H 2 O 2 and H + induces polarization of M2 macrophages to M1. This, in conjunction with anti-PD-L1, activates T cells, enhancing the effectiveness of immunotherapy. Traditional treatments against advanced non-small cell lung cancer (NSCLC) with high morbidity and mortality continue to be dissatisfactory. Given this situation, there is an urgent requirement for alternative modalities that provide lower invasiveness, superior clinical effectiveness, and minimal adverse effects. The combination of photodynamic therapy (PDT) and immunotherapy gradually become a promising approach for high-grade malignant NSCLC. Nevertheless, owing to the absence of precise drug delivery techniques as well as the hypoxic and immunosuppressive characteristics of the tumor microenvironment (TME), the efficacy of this combination therapy approach is less than ideal. In this study, we construct a novel nanoplatform that indocyanine green (ICG), a photosensitizer, loads into hollow manganese dioxide (MnO 2 ) nanospheres (NPs) (ICG@MnO 2 ), and then encapsulated in PD-L1 monoclonal antibodies (anti-PD-L1) reprogrammed exosomes (named ICG@MnO 2 @Exo-anti-PD-L1), to effectively modulate the TME to oppose NSCLC by the synergy of PDT and immunotherapy modalities. The ICG@MnO 2 @Exo-anti-PD-L1 NPs are precisely delivered to the tumor sites by targeting specially PD-L1 highly expressed cancer cells to controllably release anti-PD-L1 in the acidic TME, thereby activating T cell response. Subsequently, upon endocytic uptake by cancer cells, MnO 2 catalyzes the conversion of H 2 O 2 to O 2 , thereby alleviating tumor hypoxia. Meanwhile, ICG further utilizes O 2 to produce singlet oxygen ( 1 O 2 ) to kill tumor cells under 808 nm near-infrared (NIR) irradiation. Furthermore, a high level of intratumoral H 2 O 2 reduces MnO 2 to Mn 2+ , which remodels the immune microenvironment by polarizing macrophages from M2 to M1, further driving T cells. Taken together, the current study suggests that the ICG@MnO 2 @Exo-anti-PD-L1 NPs could act as a novel drug delivery platform for achieving multimodal therapy in treating NSCLC. Graphical abstract Herein, we have constructed hollow MnO 2 NPs loaded with ICG (ICG@MnO 2 ), and then are encapsulated in DCs-derived exosomes treated with azide choline (AECho) via click chemistry reaction to obtain ICG@MnO 2 @Exo. The exosomes are reprogrammed using PD-L1 monoclonal antibodies (anti-PD-L1), generating ICG@MnO 2 @Exo-anti-PD-L1 to effectively modulate the TME and combat NSCLC through the synergistic effects of PDT and immunotherapy. In detail, an LLC (lewis lung carcinoma cells) allograft model in C57BL/6 mice was constructed and ICG@MnO 2 @Exo-anti-PD-L was injected through the tail vein. By specifically targeting cancer cells with high PD-L1 expression, the ICG@MnO 2 @Exo-anti-PD-L1 nanospheres (NPs) are precisely delivered to the tumor site and release anti-PD-L1 in the acidic TME, thereby activating T cell responses. Upon internalization by cancer cells, MnO 2 catalyzes the conversion of hydrogen peroxide (H 2 O 2 ) to oxygen, alleviating tumor hypoxia. In addition, ICG utilizes oxygen to generate singlet oxygen ( 1 O 2 ) under near-infrared (NIR) irradiation at 808 nm, leading to the destruction of tumor cells. Furthermore, the high levels of intratum oral H 2 O 2 and H + reduces MnO 2 to Mn 2+ , which remodels the immune microenvironment by polarizing macrophages from M2 to M1, thereby further stimulating T cell responses. Collectively, the findings of this study suggest that ICG@MnO 2 @Exo-anti-PD-L1 NPs can serve as a novel drug del -Abstract Truncated-

A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

Oral delivery of anti-PD-L1 antibody for cancer immunotherapy against orthotopic colorectal tumors

Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD‐L1 Expression for Circumventing Immune Resistance of Cancer

PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Preclinical anti-tumor activity of small-molecule oral PD-L1 checkpoint inhibitors.

1197 Site-specific Anti-Pd-1-irgd Peptide Conjugate Boosts Antitumor Efficacy Via Enhancement of T Cell Penetration and Engagement

Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation

Platinum-Based Nanovectors Engineered with Immuno-Modulating Adjuvant for Inhibiting Tumor Growth and Promoting Immunity

A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer

Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement

Co-Delivery of Doxorubicin and Anti-PD-L1 Peptide in Lipid/PLGA Nanocomplexes for the Chemo-Immunotherapy of Cancer

Nano-Liposome Co-Loaded with C-X-C Chemokine Ligand 12/CXCR4 Pathway Inhibitor Synergistically Increases the Immune Efficacy of Anti-PD-L1 and Increase Anti-Tumor Activity of Effector T Cells

Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer

Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

474P Evaluation of Gelatinase-Responsive Copolymeric Nanoparticles Targeting PD-1 and TGF-β Pathways for Treating Immune-Resistant Tumor

Sequential Delivery of PD-1/PD-L1 Blockade Peptide and IDO Inhibitor for Immunosuppressive Microenvironment Remodeling Via an MMP-2 Responsive Dual-Targeting Liposome

PD-L1 Antibodies-Armed Exosomal Vaccine for Enhanced Cancer Immunotherapy by Simultaneously in Situ Activating T Cells and Blocking PD-1/PD-L1 Axis